 Human Immunodeficiency Virus (HIV) is the cause of Acquired Immunodeficiency Syndrome (AIDS). HIV directs the synthesis of several polyproteins, which each consist of several tandemly linked proteins. The maturation of the virus to its infectious form requires that these polyproteins be cleaved to their component proteins. HIV-1 protease, a homodimeric enzyme, is responsible for doing so and is therefore crucial to the virus's infectious capacity. Structure of HIV-1 ProteaseThe X-ray structure of HIV-1 protease reveals that it is composed of two symmetrically related subunits, each consisting of 99 amino acid residues. The subunits come together in such as way as to form a tunnel where they meet. This tunnel is of critical importance because the active site of the protease is located in its interior. The active site consists of two Asp-Thr-Gly conserved sequences, making it a member of the aspartyl protease family. The two Asp's are essential catalytic residues that activate a water molecule to hydrolytically cleave the polyprotein that binds in the tunnel.[1] You may be wondering how a polyprotein makes its way into the active-site tunnel, as the tunnel appears to be too narrow to admit it. The key is the two flexible flaps on the top of the tunnel that move to allow proteins to enter the tunnel. The flaps undergo a dramatic movement, shifting from an open to a closed conformation to bind the target in an appropriate conformation for cleavage. Medical ImplicationsThere currently is no cure or vaccine against HIV. Researchers, however, have discovered treatments that can halt and even reverse the progression of AIDS, due in large part to our understanding of the structure of HIV-1 protease. Saquinavir (Invirase) was the first protease inhibitor approved by the FDA for the treatment of HIV. It inhibits HIV protease by binding tightly in the active site tunnel, preventing the binding of polyproteins. Its chemical structure mimics the tetrahedral intermediate of the hydrolytic reaction, thereby interacting strongly with the catalytic Asp residues.[2] Saquinavir is essentially an uncleavable ligand, as indicated by the similar conformational changes in the protease flaps on binding saquinavir or a polypeptide . Other drugs used to treat HIV infection that inhibit HIV protease include Indinavir (Crixivan), Ritonavir (Norvir), and Nelfinavir (Viracept).
| ||||||||||||
For additional information, see: Invirase
This page was last modified 20:07, 7 July 2011.